Barcelona soccer star Lamine Yamal is facing scrutiny after he allegedly hired people with dwarfism to entertain guests at ...

Performers defend their presence at the footballer’s 18th birthday and reject a statement made on their behalf by a ...

The Association of People with Achondroplasia and other Skeletal Dysplasias in Spain (ADEE) said in a statement that it “denounces the hiring of people with dwarfism as entertainment” at the party.

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I'm downgrading BMRN stock to Hold.

Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Achondroplasia Treatment Market size was valued at about USD 120.4 million in 2024 and expected to grow at ...

Barcelona forward Lamine Yamal is back in training with the rest of his teammates this week as the Catalan side begin preparations for the new season. The teenage superstar ended his summer in ...

A Spanish disability rights group has vowed legal action over the reported hiring of people with dwarfism as entertainment at Barcelona soccer star Lamine Yamal's recent 18th birthday party, ...

Marketresearch.biz reports that the Achondroplasia Market size is expected to be worth around USD 1427.7 Bn by 2032 from USD 68.7 Bn in 2022, growing at a CAGR of 36.5% during the forecast period from ...

Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Child & Adolescent Health. doi.org ...

Achondroplasia, caused by a dominant mutation in the FGFR3 gene, is the most common form of disproportionate short stature and has no approved pharmacologic therapy, apart from growth hormone in ...

Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. BridgeBio will also host an investor call on March 6, 2023, at 7:30 am ET to discuss the ...

Achondroplasia is a genetic bone disorder affecting about one in every 25,000 infants. It is caused by a mutation in the FGFR3 gene that impairs the growth of bones in the limbs, the spine, and ...